The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015-Reference-Cited by-同舟云学术

The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015

Published:2017-05-19 Issue:8 Volume:26 Page:977-983
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

van Hunsel Florence¹^ORCID,de Waal Susan¹²,Härmark Linda¹

Affiliation:

1. Netherlands Pharmacovigilance Centre Lareb; WHO Collaborating Centre For Pharmacovigilance In Education And Patient Reporting; 's-Hertogenbosch The Netherlands

2. Pharmaceutical Business Administration, Institute for Allied Healthcare; Utrecht University of Applied Sciences; Utrecht the Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference26 articles.

1. Evaluation of FDA safety-related drug label changes in 2010;Lester;Pharmacoepidemiol Drug Saf,2013

2. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee;Pacurariu;Drug Saf,2014

3. CIOMS Working Group VIII Practical aspects of signal detection in pharmacovigilance: report of CIOMS working group VIII 2010

4. The validity and reliability of a signal impact assessment tool;Rolfes;Pharmacoepidemiol Drug Saf,2016

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a core outcome set for cardiovascular diabetology: a methodological framework;Frontiers in Endocrinology;2023-12-06

2. Factors that influence patient and public adverse drug reaction reporting: a systematic review using the theoretical domains framework;International Journal of Clinical Pharmacy;2023-05-29

3. Sample Bias in Web-Based Patient-Generated Health Data of Dutch Patients With Gastrointestinal Stromal Tumor: Survey Study;JMIR Formative Research;2022-12-15

4. Development of a multivariate prediction model to identify individual case safety reports which require clinical review;Pharmacoepidemiology and Drug Safety;2022-10-21

5. Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports;Drug Safety;2022-01-12